Publications (137) View all
-
Article: Hoch intensiver fokussierter transrektaler Ultraschall (rHIFU) zur lokalen Therapie des Prostatakarzinoms
[show abstract] [hide abstract]
ABSTRACT: Gepulster fokussierter, robotischer hoch intensiver Ultraschall (rHIFU) ist v.a. aufgrund seines nicht invasiven Therapiecharakters interessant. In der urologischen Onkologie findet rHIFU als therapeutische Maßnahme zur transrektalen Behandlung des Prostatakarzinoms Anwendung. Während die perkutane Therapie des Nierenkarzinoms derzeit noch in experimentell klinischen Studien geprüft wird, ist die transrektale Therapie mit rHIFU bereits in über 230 urologischen Abteilungen weltweit als Therapieoption des Prostatakarzinoms etabliert. Die Ergebnisse der Therapie des Prostatakarzinoms mit rHIFU basieren in der Hauptsache auf Patientenserien unterschiedlicher klinischer Studien. In den USA wurde vor 2Jahren eine prospektive Multicenterstudie für die klinische Zulassung (FDA Approval) begonnen (Vergleich HIFU/Kryotherapie). Die neuesten Publikationen sehen in der transrektalen Anwendung von rHIFU eine Erfolg versprechende zusätzliche Therapieoption beim lokalen Prostatakarzinom, bei lokalen Rezidiven jedweder erfolgloser Primärtherapien, sowie als palliativ adjuvante Zusatztherapie des systemischen Prostatakarzinoms. Pulsed robotic high-intensity focused ultrasound (rHIFU) is an interesting therapeutic option mainly due to its noninvasive character. In urologic oncology, rHIFU is used for the transrectal therapy of prostate cancer. While percutaneous therapy of renal cancer using rHIFU is still being tested in experimental studies, transrectal therapy with rHIFU for prostate cancer is already established in more than 230 urologic departments worldwide. The results of prostate cancer therapy with rHIFU are mainly based on different clinical studies. In 2007 a clinical study comparing rHIFU and cryotherapy for the treatment of prostate cancer was initiated in the USA in order to gain clinical approval by the FDA. The most recent publications concluded that the use of rHIFU is an effective standard treatment for prostate cancer with a broad range of indications in all tumor stages: (1) in the primary treatment of local prostate cancer, (2) in patients with local recurrence after failure of any primary treatment, and (3) as an adjuvant therapy in the palliation of systemic prostate cancer.Der Urologe 04/2012; 48(7):710-718. · 0.50 Impact Factor -
Article: [Transrectal high-intensity focused ultrasound for local treatment of prostate cancer. 2009 Update].
[show abstract] [hide abstract]
ABSTRACT: Pulsed robotic high-intensity focused ultrasound (rHIFU) is an interesting therapeutic option mainly due to its noninvasive character. In urologic oncology, rHIFU is used for the transrectal therapy of prostate cancer. While percutaneous therapy of renal cancer using rHIFU is still being tested in experimental studies, transrectal therapy with rHIFU for prostate cancer is already established in more than 230 urologic departments worldwide. The results of prostate cancer therapy with rHIFU are mainly based on different clinical studies. In 2007 a clinical study comparing rHIFU and cryotherapy for the treatment of prostate cancer was initiated in the USA in order to gain clinical approval by the FDA. The most recent publications concluded that the use of rHIFU is an effective standard treatment for prostate cancer with a broad range of indications in all tumor stages: (1) in the primary treatment of local prostate cancer, (2) in patients with local recurrence after failure of any primary treatment, and (3) as an adjuvant therapy in the palliation of systemic prostate cancer.Der Urologe 06/2009; 48(7):710-8. · 0.50 Impact Factor -
Article: High-intensive focused ultrasound in localized prostate cancer.
[show abstract] [hide abstract]
ABSTRACT: The results of the standard treatment for prostate cancer-radical prostatectomy-are not entirely satisfactory. A new local therapy, transrectal high-intensive focused ultrasound (HIFU), has been developed. We reviewed our experience with HIFU for palliation of localized prostate cancer. Our series included 65 men with confirmed prostate cancer without detectable metastases who were not suitable candidates for radical prostatectomy. After prophylactic suprapubic cystostomy, the patients were treated using the Ablatherm version 2.32 under spinal anesthesia. The effects were monitored by serum prostate specific antigen assays, digital rectal examination, and biopsy. The mean follow-up is 10 months (range 1-18 months). There were no intraoperative or postoperative deaths, and there have been no deaths from prostate cancer. Residual cancer was detected in 35% of the patients in whom only biopsy-positive portions of the prostate were treated and 17% of those in whom the entire gland was treated. Retreatment was performed 1 month after the first session in these patients. The prostate volume increased an average of 30% after treatment, but by 3 months, the gland was 10% to 20% smaller than its original size. Three patients suffered complications secondary to overheating of the rectal wall or treatment too close to the external urethral sphincter. The low morbidity, minimal invasiveness, avoidance of systemic side effects, and potentially curative effect make HIFU a potentially useful option for the treatment of localized prostate cancer.Journal of Endourology 05/2000; 14(3):293-9. · 1.85 Impact Factor -
Article: First clinical experience and in situ treatment of ureteric stones using Lithostar Multiline lithotripter.
[show abstract] [hide abstract]
ABSTRACT: This article reviews the first experience using the Siemens Lithostar Multiline lithotripter in 372 consecutive treatments of ureteric and kidney stones. The disintegration rate was 97.7%, and a stone-free rate of 87% was achieved at the end of 3 months. Auxillary procedures were required in only 11% of the patients. No medication was required for pain management in 60.4% of the patients. The results were especially impressive in the management of ureteric stones, with a success rate of 91%, these patients being stone free after 1 week using the new booster technique. Analysis of the data indicates that the Siemens Lithostar Multiline is a safe, effective, and economically sound device to treat patients with ureteric and renal stones.Journal of Endourology 11/1995; 9(5):367-70. · 1.85 Impact Factor -
Article: Optimizing treatment for middle and distal ureteral calculi.
Contemporary urology 09/1995; 7(8):60-2, 65-6, 68-70.
